Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: AIDS Behav. 2020 Jan;24(1):274–283. doi: 10.1007/s10461-019-02616-3

Figure 1:

Figure 1:

Predicted and Observed HIV Infection Risk in EXPLORE, VAX004, HIV Prevention Trials Network 061, and HIV Vaccine Trials Network 505 Cohort Studies.*

* C-statistics for internal validation in the development cohort EXPLORE=79.5; and external validation cohorts VAX004=73.1, HPTN 061=71.0, and HVTN 505=71.9. The Sex Pro Score risk strata of 16–20 for HPTN 061 is blank because all participants in this cohort had predicted and observed Sex Pro scores of <16.